MaxCyte, Inc. (MXCT)
- Previous Close
4.8000 - Open
4.8500 - Bid 4.6300 x 100
- Ask 4.6900 x 200
- Day's Range
4.6600 - 4.8850 - 52 Week Range
2.4500 - 5.5450 - Volume
271,236 - Avg. Volume
562,224 - Market Cap (intraday)
497.439M - Beta (5Y Monthly) 1.07
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3500 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.25
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
www.maxcyte.comRecent News: MXCT
Performance Overview: MXCT
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MXCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MXCT
Valuation Measures
Market Cap
496.74M
Enterprise Value
357.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.98
Price/Book (mrq)
2.16
Enterprise Value/Revenue
8.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-83.00%
Return on Assets (ttm)
-10.98%
Return on Equity (ttm)
-15.42%
Revenue (ttm)
44.05M
Net Income Avi to Common (ttm)
-36.57M
Diluted EPS (ttm)
-0.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
157.51M
Total Debt/Equity (mrq)
8.23%
Levered Free Cash Flow (ttm)
-17.42M
Research Analysis: MXCT
Company Insights: MXCT
MXCT does not have Company Insights